Histone deactylase inhibitors (HDACis) show promise as cancer therapeutics, however, the full scope of their utility remains unknown. Here we report findings that strongly rationalize clinical evaluation of HDACis in malignant peripheral nerve sheath tumors (MPNSTs), a class of highly aggressive, therapeutically resistant and commonly fatal malignancies that occur sporadically or in patients with the inherited neurofibromatosis type 1 (NF1) syndrome. We evaluated the effects of the chemical HDACis PCI-24781, SAHA, and MS-275 on a panel of human NF1-associated and sporadic MPNSTs in vitro and in vivo. A subset of MPNSTs were found to be highly sensitive to HDACis, especially to PCI-24781. All cell-lines in this group were NF1-associated. Significant proapoptotic effects were noted in vitro and in vivo and were independent of p53 mutational status. In contrast, as a group the sporadic MPNST cells were markedly resistant to HDACi treatment. HDACis were found to induce productive autophagy in MPNST cells. Research.
Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are rare malignancies originating from Schwann lineage cells and arising proximate to peripheral nerves (1, 2). MPNSTs account for 3-10% of all soft tissue sarcomas (STS) and are a highly aggressive histological-subtype (3-5). >50% occur in patients with the inherited neurofibromatosis type-1 (NF1) syndrome; ~8-12% of NF1 patients will develop an MPNST in their lifetime, commonly arising within a pre-existing deep, plexiform neurofibroma (6, 7); the remainder develop sporadically (6). In adults with NF1, MPNSTs are the most common malignancy, the major source of morbidity, and the leading cause of NF1-related mortality (8, 9). Complete surgical resection, frequently not feasible due to local invasiveness and/or uncontrollable metastases, is the only potentially curative option; Statistics: Cell culture-based assays were repeated at least thrice; mean ± SD was calculated. Cell-lines were examined separately. For outcomes that were measured at a single time point, two-sample t-tests were used to assess the differences. Differences in xenograft growth (tumor/metastases) in vivo were assessed using a two-tailed Student's t-test. Significance was set at P 0.05.
Results

HDACis induce significant apoptosis in a subset of human MPNST
HDACi effects on human MPNST cell growth and clonogenicity were evaluated. Six Higher doses of SAHA and MS-275 were needed to achieve PCI-24781-equivalent MPNST growth-inhibition; however, a similar response pattern was found for all these drugs, enabling MPNST cell designations to "sensitive" and "resistant" cohorts ( Fig 1A) .
A similar pattern of response was noted when the effect of HDACis on colony-forming capacity was evaluated (Fig 1B) . This pattern was also reflected in the induction of apoptosis by these compounds (Fig 1C) . Marked apoptosis (evaluated by Annexin-V/PI staining FACS analysis) was seen in "sensitive" cell-lines while no significant apoptosis Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research was induced in "resistant" cells. Similarly, an increase in cleaved caspase-3 was seen in "sensitive" but not in "resistant" cells (Fig 1C) . A time-and dose-dependent increase in target protein acetylation could be observed in all the cell lines regardless of the growth inhibitory effects (Fig 1D) . This aligns with previous published data demonstrating that protein acetylation occurs even in normal cells which are relatively resistant to HDACi effects suggesting that while drugs are delivered into the cells and reach their intended targets, additional molecular mechanisms drive therapeutic sensitivity and resistance (21) .
Since HDACis have also been shown to exert anti-tumor effects through activation of wild-type p53 (22), and p53 deregulation is a common event in MPNST (23)
the p53 mutational status of these cells was evaluated (Fig S2A) . These studies indicated that in MPNST, HDACi response is independent of p53 mutation/function.
Interestingly, we observed that all MPNST cells in the "sensitive" group are NF1-associated while both "resistant" cell-lines are sporadic (Fig S2B) .
HDACi sensitivity/resistance pattern is recapitulated in vivo
Human MPNST xenografts (Fig S1) , including HDACi "sensitive" (MPNST642) and "resistant" (MPNST724 and STS26T) tumors, were used to evaluate the effects of HDACi on tumor growth in vivo. PCI-24781 was selected due to its enhanced efficacy in vitro. As shown in Fig 2A, 
HDACis induce autophagy in MPNST cells in vitro and in vivo
To further evaluate HDACi-induced structural changes in "resistant" cells, transmission electron microscopic (TEM) evaluation was conducted: a large number of cytoplasmic autophagosomes was noticed after treatment (24 [ Fig 3A] , 48, and 72 hr) but no signs of apoptosis were seen. While the noted autophagosome accumulation suggests druginduced autophagy, multiple assays are needed to confirm this observation (24).
Acridine-orange staining demonstrated increased acidic vesicular organelles (AVOs) in PCI-24781 (0.5µM/24hr) treated compared to control DMSO treated cells, as was confirmed via FACS analysis (Fig 3B) . Furthermore, LC3B conversion and LC3B-II expression (normalized to actin) both increased after treatment with all three HDACis tested (Fig 3C) . Since the experiments described above may represent either enhanced autophagosome synthesis and productive autophagy or reduced autophagosome turnover due delayed trafficking or reduced autophagosome-lysosome fusion (24), cells were pretreated (1hr) with low doses of the autophagy inhibitors Bafilomycin A1 (1nM) or chloroquine (1µM) prior to PCI-24781 treatment (24hr). PCI-24781 treatment produced increased LC3B-II expression even in the presence of these inhibitors, providing evidence of efficient autophagic flux (Fig 3C) . Furthermore, cells stably transduced to express LC3-GFP, exhibited increased GFP puncta in response to HDACi treatment (Fig 3D) . WB demonstrated increased GFP cleavage following HDACi treatment that (Fig 3D) . Similarly, HDACi-induced autophagy could be observed in vivo. Animals bearing STS26T tumors were treated with PCI-24781 for four days and on day five tumors were harvested two, four, and six hours after final dose. WB analysis demonstrated a time-dependent increase in LC3B-II expression (Fig 3D) . Similarly, MPNST724/GFP-LC3 xenografts were treated with PCI-24781, chloroquine, or their combination (Fig 3D) . A marked increase in free GFP expression was noted in response to PCI-24781. Chloroquine blocked HDACi-induced increases in free GFP.
HDACi-induced autophagy was not exclusive to sporadic MPNST cells and in a series of experiments as depicted above we found autophagy to occur in response to PCI-24781 in all NF1-assciated HDACi "sensitive" cells ( Fig S3) . However, in contrast to the MPNST 'resistant' cells, morphologic features of apoptosis were also present.
Together, our data strongly support that HDACis induce productive autophagy in
MPNST cells in vitro and in vivo.
Autophagy blockade enhances HDACi pro-apoptotic effects in MPNST cells
It is currently unclear whether drug-induced autophagy contributes to cell death or possibly represents a mechanism of therapeutic resistance (25, 26). To that end, we evaluated the impact of autophagy-blockade using complementary genetic and pharmacological manipulations on HDACi-induced effects. siRNA knockdown of beclin, ATG5, and ATG7 were conducted (Fig 4A-C) . Autophagy blockade was assessed via LC3B-II WB; knockdown of any of the three targets decreased both baseline and PCI-24781-induced LC3B-II expression. Most importantly, enhanced apoptosis in response to PCI-24781 pretreatment of cells was found after target knockdown, as determined via PARP cleavage and Annexin-V/PI FACS analysis (Fig 4A-C) . Pharmacologic autophagy inhibition was achieved using bafilomycin and chloroquine (Fig 4D) . The clonogenic Next, we evaluated the impact of autophagy blockade on "sensitive" MPNST cell lines where autophagy in response to HDACi occurs in parallel with apoptosis. Using an experimental approach as per above we found that blocking autophagy significantly enhanced apoptosis both when low doses (0.1µM/24h) and high doses (1µM/24h) of PCI24781 were used (Fig S3) . These data suggests that even in HDACi sensitive cells autophagy is a potential survival mechanism opposing apoptosis.
Autophagy blockade enhances HDACi pro-apoptotic effects in vivo
Next, we evaluated the effects of autophagy-blockade on HDACi treatment response in vivo. MPNST724 and STS26T xenografts were used and therapy was initiated when tumors reached a mean diameter of 0.5cm (Fig 5A&B) . No major side-effects were noted. No significant growth inhibition was seen with PCI-24781 or choloroquine as monotherapy. However, chloroquine/PCI-24781 combination significantly inhibited tumor growth in both animal models as compared to control and either of the compounds alone (p<0.05). A significant increase in apoptosis was observed in combination-treated tumors as determined by TUNEL staining (p<0.05; Fig 5C) .
Next, an experimental MPNST lung metastasis model ( Fig S1) was used; therapy was initiated a week after tail-vein injection and continued for two wks (Fig 5D) .
All control (n=6), PCI-24781 (n=7) and chloroquine (N=7) treated mice exhibited extensive macroscopic lung metastases at study termination, whereas in 3/7
Research. 
HDACi-induced autophagy related gene-expression changes
Due to their mechanisms of function, one of the major consequences of HDACi therapy is gene expression modulation. Using a focused autophagy PCR array, we sought to identify potential autophagy-related genes in MPNST cells whose expression is modified secondarily to HDACi treatment. Results revealed four genes that were reproducibly over-expressed in both cell-lines and five that were consistently down-regulated (Table   S1 ). Three over-expressed genes (IRGM, CXCR4, and TMEM74) and one downregulated gene, NFκB, were selected for validation. A concordant dose-dependent increase/decrease in corresponding RNA expression levels was identified after PCI-24781 treatment (24hr; Fig 6A) . Similarly, IRGM, CXCR4, and TMEM74 mRNA expression was increased in PCI-24781 treated xenograft tissues; NFκB mRNA levels were decreased (Fig 6B) . Together, these experiments identified several targets modified by HDACi that may play a role in HDACi-induced autophagy and merit further investigation. Accordingly, IRGM, exhibiting the highest fold increased expression, was selected for additional study. To confirm that increased IRGM expression in MPNST is a common consequence of HDACi exposure, the effects of SAHA and MS-275 on IRGM mRNA expression were evaluated ( Fig 6C) ; both agents induced IRGM expression. A PCI-24781-induced increase in IRGM protein was also demonstrated. IRGM siRNA knockdown demonstrated inhibition of PCI-24781-induced autophagy as suggested by decreased LC3B-II expression (Fig 6D) . Most importantly, IRGM knockdown resulted in enhanced PCI-24781-induced apoptosis in both cell-lines. Together, our results
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analysis; B. Similar effects were noted after ATG5 knockdown. Knockdown was confirmed by RTPCR; C. As above, ATG7 knockdown (confirmed by RTPCR) resulted in increased PCI-24781 sensitivity; D. Pharmacologic autophagy-inhibition was achieved using bafilomycin and chloroquine. None of the compounds alone significantly affected the clonogenic capacity of STS26T or MPNST724; however, significant effects were noticed after chloroquine (1µM) or bafilomycin (1nM) pretreatment of cells (1hr) followed by PCI-24781 for 24hr (upper panels; p<0.05). Markedly increased apoptosis was also identified using these therapeutic combinations (lower panels). (* denotes statistically significant effects; p<0.05) 
